Famotidine
- Generic Name
- Famotidine
- Brand Names
- Duexis, Duo Fusion, Fluxid, Good Sense Acid Reducer, Pepcid, Pepcid Complete, Zantac Reformulated Aug 2022
- Drug Type
- Small Molecule
- Chemical Formula
- C8H15N7O2S3
- CAS Number
- 76824-35-6
- Unique Ingredient Identifier
- 5QZO15J2Z8
- Background
Famotidine is a competitive histamine-2 (H) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H receptor antagonists, famotidine displays high selectivity to...
- Indication
Famotidine is indicated in pediatric and adult patients (with the bodyweight of 40 kg and above) for the management of active duodenal ulcer (DU), active gastric ulcer, symptomatic non-erosive gastroesophageal reflux disease (GERD), and erosive esophagitis due to GERD, diagnosed by biopsy.
...
- Associated Conditions
- Chronic Back Pain, Duodenal Ulcer, Erosive Esophagitis, Extra-Articular Rheumatism, Gastritis, Heartburn, Helicobacter Pylori Infection, Multiple Endocrine Neoplasia, Muscle Spasms, Nonspecific Pain Post Traumatic Injury, Osteoarthritis (OA), Postoperative pain, Stress Ulcers, Symptomatic Non-erosive Gastroesophageal Reflux Disease, Zollinger-Ellison Syndrome, Active Gastric ulcer, Acute Duodenal Ulcers, Gastrointestinal ulceration, Pathological hypersecretory conditions
- Associated Therapies
- -
Effect of Tegoprazan for Elective Surgery Patients Under General Anesthesia
- Conditions
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Kim, Young Sung
- Target Recruit Count
- 174
- Registration Number
- NCT06743243
- Locations
- 🇰🇷
Korea University Medical Center, Guro Hospital, Seoul, Korea, Republic of
A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT06207305
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Study to Assess the Effects of Itraconazole, Food, and pH on the Drug Levels of BMS-986368 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-12-14
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Celgene
- Target Recruit Count
- 32
- Registration Number
- NCT06170723
- Locations
- 🇺🇸
Local Institution - 0001, Tempe, Arizona, United States
Prevention of Post-Cardiac Surgery Acute Kidney Injury by Proton Pump Inhibitor
- First Posted Date
- 2023-12-04
- Last Posted Date
- 2024-12-02
- Target Recruit Count
- 100
- Registration Number
- NCT06154226
- Locations
- 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States
A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 132
- Registration Number
- NCT06144697
- Locations
- 🇺🇸
Local Institution - 0003, Austin, Texas, United States
🇺🇸Local Institution - 0001, Anaheim, California, United States
A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- PMV Pharmaceuticals, Inc
- Target Recruit Count
- 28
- Registration Number
- NCT06054464
- Locations
- 🇺🇸
Parexel International, Baltimore, Maryland, United States
A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
- Conditions
- Interventions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05977998
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Multimodal Pain Package vs. Regular Formulation for Pain Management in Ambulatory Spinal Surgery
- Conditions
- Interventions
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 100
- Registration Number
- NCT05965492
- Locations
- 🇺🇸
university of Miami, Miami, Florida, United States
🇺🇸University of Miami, Miami, Florida, United States
Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial
- Conditions
- Interventions
- First Posted Date
- 2023-07-14
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Emory University
- Target Recruit Count
- 5
- Registration Number
- NCT05946551
- Locations
- 🇺🇸
Grady Health System, Atlanta, Georgia, United States
🇺🇸Emory Hospital, Atlanta, Georgia, United States
🇺🇸Emory University Hospital Midtown, Atlanta, Georgia, United States
A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 76
- Registration Number
- NCT05866627
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.